This is the first major U.S. PE guideline update since 2019 (ESC published guidelines in 2019). Key advances and changes:
New Clinical Categories (A-E): Refined severity classification system integrating clinical, laboratory, and imaging parameters to improve precision of risk assessment and prognostication.
DOAC-First Approach: Direct oral anticoagulants (apixaban, rivaroxaban) now preferred over VKAs and initial parenteral therapy for long-term management due to superior efficacy and safety profiles.
Enhanced D-Dimer Strategies: Age-adjusted D-dimer thresholds and YEARS algorithm integration for more selective use of imaging in diagnostic evaluation.
PE Response Teams (PERT): Formal recommendations for multidisciplinary team-based care to improve outcomes in complex and high-risk PE cases.
Advanced Therapies: Expanded evidence for systemic thrombolysis, catheter-directed thrombolysis, and mechanical thrombectomy with clearer clinical indications.
Special Populations: Comprehensive updated guidance for PE in pregnancy, active cancer, chronic kidney disease, obesity, and elderly patients.
Diagnosis Algorithm
Clinical evaluation of suspected PE integrates pretest probability assessment with laboratory testing and imaging in a stepwise approach:
PE Diagnostic Pathway
Step 1: Evaluate pretest probability using Wells Score, Revised Geneva Score, or clinical judgment (Low <15%, Intermediate 15-50%, High >50%)
Step 2: Order D-dimer testing if low or intermediate probability; use age-adjusted or YEARS criteria for threshold interpretation
Step 3: If D-dimer elevated OR high clinical probability → Perform CTPA or V/Q imaging for definitive diagnosis
Step 4: Initiate anticoagulation immediately while awaiting imaging if high clinical suspicion
Wells Score for PE
Clinical decision tool used to stratify pretest probability. Calculate by adding points for each finding present:
Clinical Finding
Points
Clinical signs of DVT (leg swelling, pain with palpation)
3
PE more likely than alternative diagnosis
3
Heart rate >100 bpm
1.5
Immobilization (≥3 days) or surgery within 4 weeks
1.5
History of DVT or PE
1.5
Hemoptysis
1
Active cancer
1
Interpretation: <2 points = Low probability (1.3%), 2-6 points = Intermediate probability (16.2%), >6 points = High probability (40.5%)
Revised Geneva Score
Alternative pretest probability assessment tool based on clinical features and vital signs. Scores 0-3 = Low, 4-10 = Intermediate, ≥11 = High probability.
Demographics & Risk: Age >65 (1 pt), Previous DVT/PE (3 pts), Hormone use (1 pt), Recent surgery/trauma (2 pts), Active cancer (2 pts)
Clinical Findings: Unilateral leg pain (3 pts), Leg edema (3 pts), Leg swelling (2 pts)
D-Dimer Strategy
Age-Adjusted Threshold: For patients age >50, use modified threshold of (age × 10) µg/L instead of standard 500 µg/L to reduce unnecessary imaging in older adults without compromising diagnostic sensitivity.
YEARS Algorithm: Simple 3-item clinical decision rule for PE diagnosis (DVT signs, hemoptysis, PE most likely diagnosis) that can be combined with D-dimer to safely exclude PE:
If YEARS score = 0 AND D-dimer <500 µg/L → PE excluded with very low failure rate (<1%)
If YEARS score >0 AND D-dimer <1000 µg/L → PE excluded safely
Pregnancy-adapted YEARS criteria available for pregnant patients to minimize radiation exposure
Risk Stratification
AHA/ACC Acute PE Clinical Categories (A-E)
New 2026 classification system replacing previous "massive/submassive" terminology with 5 categories for improved prognostic precision:
Category A (Subclinical/Asymptomatic): Incidental PE discovered on imaging in asymptomatic patients without symptoms
Category B (Symptomatic, Low Severity): Hemodynamically stable, no RV dysfunction or myocardial necrosis, PESI class I-II
Hestia Criteria: Identifies low-risk PE patients suitable for outpatient treatment. All criteria must answer "No" for outpatient eligibility:
Hemodynamically unstable? Requires thrombolysis/embolectomy? Active major bleeding? High bleeding risk on anticoagulation?
Severe renal/hepatic impairment? Previous heparin-induced thrombocytopenia? Pregnant? Leg immobilization/fracture?
Severe pain requiring IV opioids? Unable to access anticoagulation therapy or reliable follow-up?
sPESI (Simplified PESI): Single-parameter version of 11-point PESI. Score ≥1 indicates elevated risk requiring hospitalization:
Age ≥80 years, History of cancer, Chronic cardiopulmonary disease, Systolic BP <100 mm Hg, Heart rate ≥110 bpm, O₂ saturation <90%, Altered mental status
Troponin (I/T): Elevated levels indicate RV myocardial injury; associated with increased all-cause mortality and PE-related mortality independent of hemodynamic status
BNP/NT-proBNP: Brain natriuretic peptide elevation indicates RV strain; strong prognostic value for short-term adverse outcomes
Lactate: Elevated arterial or venous lactate indicates tissue hypoperfusion; important marker of hemodynamic compromise and organ dysfunction
D-dimer clearance: Delayed D-dimer resolution may indicate persistent thrombus burden or risk of developing CTEPH
Right Ventricular Assessment
Echocardiography parameters: RV/LV diameter ratio, TAPSE, fractional area change, S' velocity, estimated systolic PA pressure
CT parameters: RV/LV diameter ratio >0.9 on axial view indicates RV dilatation; strong correlation with hemodynamic instability and adverse outcomes
Anticoagulation Therapy
Initial Anticoagulation Phase (3-6 Months)
DOAC-First Recommendation (Class 1): For most patients without absolute contraindications to anticoagulation, direct oral anticoagulants are preferred over warfarin or initial parenteral therapy due to superior efficacy, safety profile, and convenience.
DOAC Dosing Regimens
Apixaban (Eliquat)
Initial Phase: 10 mg twice daily for 7 days, then transition to maintenance dose
Maintenance Phase: 5 mg twice daily for 3-6 months (or longer if unprovoked PE)
Special Dosing: Use 5 mg twice daily if age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL
Rivaroxaban (Xarelto)
Initial Phase: 15 mg twice daily for 21 days (must take with food)
Maintenance Phase: 20 mg once daily with food for 3-6 months (or longer if unprovoked PE)
Special Dosing: Consider dose adjustment in severe renal impairment (CrCl 15-30 mL/min)
Parenteral Anticoagulation (When DOAC Cannot Be Used)
Unfractionated Heparin (UFH): Initial IV bolus 80 units/kg, then continuous IV infusion 18 units/kg/hr; preferred for severe renal impairment (eGFR <30) and situations requiring rapid reversal (major GI bleeding, imminent procedures)
LMWH (Enoxaparin): 1 mg/kg SC every 12 hours or 1.5 mg/kg SC daily; may be bridged to DOAC or VKA; requires adjusted dosing in obesity, severe renal impairment, or ICU settings
Fondaparinux: Weight-based dosing 5-10 mg SC once daily; useful in heparin-induced thrombocytopenia (HIT); contraindicated if CrCl <30 mL/min
Duration of Anticoagulation
Provoked PE (surgery, major trauma, immobilization): 3 months of anticoagulation typically sufficient; reassess if transient provocation or persistent risk
Unprovoked PE or Recurrent PE: Extended anticoagulation beyond initial 3-6 months recommended unless very high bleeding risk contraindicates continuation
Cancer-Associated PE: DOAC or LMWH preferred over warfarin; continuation duration based on active cancer treatment status (often extended beyond acute phase)
Major Single Reversible Risk Factor: Anticoagulation 3-6 months; reassess at 3 months for extent of risk factor resolution
Stage 2-3 (eGFR ≥30): All DOACs acceptable; standard dosing usually appropriate
Stage 4 (eGFR 15-29): Apixaban preferred; UFH or weight-adjusted LMWH acceptable for parenteral needs
Stage 5 (eGFR <15): Apixaban or UFH/LMWH with careful dose adjustment; avoid rivaroxaban due to renal excretion
Obesity (BMI ≥30)
Standard DOAC dosing remains appropriate even in severe obesity (no weight-based adjustments needed)
For LMWH in weight >150 kg, dose escalation of 20-25% may reduce recurrence risk
Pregnancy
LMWH or UFH strongly preferred; both safe, with LMWH commonly used for predictable dose-response
Half-life LMWH increases during pregnancy; weight-based dosing adjustments needed each trimester
DOACs and warfarin contraindicated in pregnancy (teratogenic potential for DOACs and warfarin)
Thrombolysis
Indications
Systemic Thrombolysis indicated (Class 1): AHA/ACC PE Category E1-2 (high-risk PE with cardiogenic shock). Class 2a-b in selected Category C-D patients with acceptable bleeding risk and clinical deterioration despite anticoagulation.
Thrombolytic Agents
Thrombolytic Agent
Standard Dose
Half-Dose Option
Administration Route
Alteplase (rt-PA)
100 mg IV over 2 hours
50 mg IV over 2 hours
IV bolus or continuous infusion
Tenecteplase (TNK)
0.5-0.6 mg/kg IV (max 50 mg)
25-30 mg IV
Single IV bolus over 5-10 seconds
Urokinase
4400 units/kg bolus, then infusion 4400 units/kg/hr
Not typically used
IV infusion
Catheter-Directed Thrombolysis (CDT)
Indications: AHA/ACC PE Category E1 (with or without shock); Class 2a-b for select Category C-D with intermediate-high risk and acceptable bleeding risk
Technique: Fluoroscopically-guided catheter delivery of thrombolytic agent directly to pulmonary artery thrombus; permits lower systemic doses and faster clot dissolution
Advantages: Reduced bleeding risk compared to systemic lysis, faster symptom relief, potential RV function improvement with reduced emboli
Newer approaches: Catheter-fragmentation, mechanical extraction, ultrasound-assisted thrombolysis combinations available
Mechanical Thrombectomy (MT)
Indications: AHA/ACC PE Category E1 (high thrombus burden); Class 2a-b for Category C-D with high-risk features and minimal bleeding risk
FLAME Trial Evidence: 115 high-risk patients; MT showed superior RV function improvement vs. anticoagulation alone (32% vs. 7% RV/LV ratio improvement at 30 days)
Outcomes: Best results reported in high-volume specialized centers with extensive operator experience
Advanced Therapies & PERT
Pulmonary Embolism Response Team (PERT)
Recommendation (Class 1): Implement high-functioning multidisciplinary PERT in all hospitals managing AHA/ACC PE Categories D-E to improve outcomes through coordinated risk assessment and therapy selection
Key Benefits of PERT Implementation:
Enhanced risk stratification and prognostication accuracy
Expedited anticoagulation and advanced therapy initiation
Appropriate selection and timing of interventions (thrombolysis, CDT, MT, surgical embolectomy)
Reduced hospital length of stay and ICU time requirements
Evidence-based pathway implementation and staff education
Improved multidisciplinary communication and coordinated patient care
Support personnel: Nursing, Pharmacy, Patient/Family representatives, Hospital Administration
Inferior Vena Cava (IVC) Filters
Indication (Class 1): Acute PE with contraindication to anticoagulation when filter is deemed necessary; retrievable filters strongly preferred
Retrievable IVC filters: Should be removed as soon as anticoagulation contraindication resolves; FDA recommends removal ≤54 days of placement
Permanent filters: Reserved for rare cases where long-term anticoagulation absolutely contraindicated due to life-threatening bleeding risk
Efficacy limitations: Filters reduce PE recurrence risk but increase DVT risk; no demonstrated mortality benefit in RCTs
Special considerations: Free-floating thrombus or very high clot burden may prompt consideration of IVC filter adjunctive to advanced therapy
Hemodynamic & Respiratory Support
Vasopressors/Inotropes: Norepinephrine first-line for hypotension; low-dose dobutamine or milrinone adjunctive in cardiogenic shock states
Mechanical Circulatory Support: VA-ECMO can serve as bridge to reperfusion therapy in Category E2 (refractory shock) patients
Fluid Management: Cautious fluid expansion in normovolemic patients; avoid pulmonary vasodilation aggravation in RV failure states
Sedation Strategy: Avoid sedatives/opioids that reduce sympathetic tone; prepare for potential hemodynamic collapse with intubation
Special Populations
PE in Pregnancy
Diagnosis: Pregnancy-adapted YEARS criteria can safely exclude PE; CTPA remains imaging standard (low fetal radiation risk; pregnancy lower threshold for imaging)
Anticoagulation: LMWH or UFH strongly preferred (Class 1); DOACs and warfarin absolutely contraindicated
Dosing Considerations: Weight-adjusted LMWH requires dosing adjustments each trimester; anticoagulation continued through delivery and ≥6 weeks postpartum
PE in Active Cancer
Preferred Anticoagulation: DOAC (apixaban 5 mg BID) or LMWH preferred over warfarin (Class 1) due to superior efficacy and safety
Duration: Extended anticoagulation beyond initial 3-6 months recommended while cancer active or undergoing treatment
LMWH Considerations: Consider 20-25% dose escalation if concern for reduced bioavailability; regular follow-up monitoring
PE in Chronic Kidney Disease
Stage 2-3 (eGFR ≥30): All DOACs safe with standard dosing; agents preferred for most patients
Stage 5 (eGFR <15): Apixaban or UFH/LMWH with careful dose adjustment; avoid rivaroxaban due to renal excretion requirements
PE in Elderly Patients
Increased baseline bleeding risk; DOACs show similar or superior safety compared to warfarin with better efficacy
sPESI scoring aids risk stratification; consider outpatient management in carefully selected low-risk elderly patients
Monitor for medication interactions and renal function deterioration requiring anticoagulation adjustment
PE in Obesity (BMI ≥30)
Standard DOAC dosing appropriate regardless of body weight or BMI
LMWH dose escalation of 20-25% may be considered if weight >150 kg to achieve adequate anticoagulation
Higher recurrence PE risk identified; consider extended anticoagulation discussion beyond standard 3-6 months
Subsegmental PE
Definition: PE confined to subsegmental pulmonary artery branches on CTPA imaging
Management: Anticoagulation recommended if alternative explanations for symptoms are excluded and no absolute anticoagulation contraindication present
Monitoring: Close clinical follow-up for symptom resolution; assess for proximal PE development during anticoagulation course
Follow-up Care & Chronic Complications
Post-Acute PE Management
Timing of Follow-up: Clinical visit within 1 week of discharge; 2-4 week visit to assess anticoagulation adherence and bleeding complications; 3-month visit to discuss anticoagulation duration and risk reassessment
Symptom Assessment: Ask about persistent dyspnea, chest pain, leg edema; evaluate for functional limitations in activities of daily living
CTEPH Screening: All patients should be screened for chronic thromboembolic pulmonary disease signs/symptoms at 3-6 month follow-up (dyspnea, exercise intolerance, RV dysfunction on echo)
Management: Referral to specialized CTEPH center for evaluation of pulmonary endarterectomy candidacy or medical therapy with PDE5 inhibitors/endothelin antagonists
Persistent Symptoms After Acute PE
Diagnostic Approach: Distinguish between post-PE syndrome (symptoms without objective findings), CTEPH, and alternative diagnoses (chronic lung disease, cardiac dysfunction, deconditioning)
Functional testing (6-minute walk test, cardiopulmonary exercise testing) may quantify exercise limitation
Pulmonary rehabilitation programs show documented benefit for dyspnea reduction and exercise capacity improvement
Psychosocial assessment important; depression, anxiety, and post-traumatic stress common after PE
Do's and Don'ts
DO:
Initiate anticoagulation early in high-probability PE while awaiting imaging confirmation.
Use age-adjusted D-dimer thresholds or YEARS algorithm to reduce unnecessary imaging studies.
Prefer DOACs (apixaban, rivaroxaban) over warfarin for initial and extended anticoagulation in most patients.
Measure troponin and BNP/NT-proBNP in all acute PE to aid risk stratification and prognostication.
Assess RV size/function on CTPA or echocardiography to refine clinical category assignment.
Activate PERT early for AHA/ACC PE Categories D-E to facilitate advanced therapy discussion and selection.
Use sPESI or Hestia criteria to identify low-risk patients suitable for outpatient treatment consideration.
Screen for PE-related dyspnea and functional impairment at 3-month follow-up; evaluate for CTEPH if persistent.
Extend anticoagulation beyond 3-6 months in unprovoked PE and cancer-associated PE unless very high bleeding risk.
Use retrievable IVC filters in patients with true anticoagulation contraindication; plan for removal timeline.
DON'T:
Routinely obtain imaging in all patients with low D-dimer and low pretest probability findings.
Use standard 500 µg/L D-dimer cutoff in older adults; apply age-adjusted thresholds instead.
Initiate systemic thrombolysis in low-risk or stable intermediate-risk PE without shock manifestations.
Place permanent IVC filters routinely; use retrievable filters with planned removal timeline.
Use V/Q SPECT/CT as first-line imaging; CTPA preferred for diagnosis and RV assessment.
Delay anticoagulation while awaiting imaging in high-risk patients with strong clinical suspicion.
Discontinue anticoagulation at 3-month mark in unprovoked PE without thorough risk reassessment discussion.
Dismiss persistent symptoms at follow-up; systematically evaluate for CTEPH and alternative diagnoses.
Recommend routine cancer screening in unprovoked PE without high-risk clinical features present.
Attempt advanced interventions (CDT, MT, surgical embolectomy) without appropriate PERT input or center experience.
Clinical Calculators & Decision Tools
Interactive calculators and tools to aid risk stratification, dosing decisions, and PE management: